Ascendis Pharma grants employees 28,030 warrants

Available on EDGAR 11/12/2026 - 04:01 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ascendis Pharma A/S (ASND) granted 28,030 warrants to certain employees on November 10, 2026. Each warrant confers the right to subscribe for one ordinary share at an exercise price of US $256.59 per share, equal to the closing price of the ordinary shares on the grant date.

Twenty-five percent of the warrants will vest on the one-year anniversary of the grant; the remaining 75% will vest at a rate of 1/36th per month from one year after the grant, subject to continued service. Earlier vesting may occur upon certain exit events. After the grant, warrants to subscribe for an additional 1,431,143 shares remained available for future grants by the board. Ascendis amended its Articles of Association to provide for the grant.

Key Figures

Warrants granted: 28,030 warrants Exercise price: US $256.59 per share Shares per warrant: 1 ordinary share +3 more

6 metrics

Warrants granted 28,030 warrants Granted to certain employees on November 10, 2026

Exercise price US $256.59 per share Equal to the closing price of the ordinary shares on the date of grant

Shares per warrant 1 ordinary share Each warrant confers the right to subscribe for one ordinary share

Shares underlying warrants available for future grants 1,431,143 shares Available after giving effect to the grant

Initial vesting 25% Vests on the one-year anniversary of the grant date

Remaining vesting 75% Vests at a rate of 1/36th per month from one year after the grant, subject to continued service

Key Terms

exercise price, vesting, exit events, Articles of Association

4 terms

exercise price financial

"has an exercise price equal to US $256.59 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting technical

"25% of the Warrants will vest on the one year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exit events technical

"Subject to earlier vesting upon the occurrence of certain exit events"

Articles of Association technical

"amended its Articles of Association to provide for the grant"

A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many warrants did ASND grant to employees?

Ascendis Pharma A/S granted 28,030 warrants to certain employees on November 10, 2026. Each warrant confers the right to subscribe for one ordinary share.

What is the exercise price for ASND's employee warrants?

Each warrant has an exercise price of US $256.59 per share, equal to the closing price of Ascendis Pharma A/S ordinary shares on the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Translation of registrant’s name into English)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Warrant Grants

On November 10, 2026, the Company’s board of directors granted an aggregate of 28,030 warrants to certain employees of the Company (the “Warrants”) under the terms of Appendix 1a to the Company’s Articles of Association. In connection with the grant of these Warrants, the Company amended its Articles of Association to provide for the grant of these Warrants. Each Warrant confers the right to subscribe for one ordinary share of the Company and has an exercise price equal to US $256.59 per share, the closing price of the Company’s ordinary shares as reported on the date of grant. Subject to earlier vesting upon the occurrence of certain exit events, 25% of the Warrants will vest on the one year anniversary of the date of grant and the remaining 75% will vest at a rate of 1/36th per month from one year after the date of grant, subject to continued service.

After giving effect to the grant of the Warrants described above, warrants to subscribe for an additional 1,431,143 shares of the Company remain available for future grant by the Company’s board of directors pursuant to the Company’s Articles of Association. The foregoing description of the material terms of the Warrants is qualified in its entirety by reference to the Company’s Articles of Association, which is included as Exhibit 1.1 hereto and incorporated by reference herein.

Exhibits

Exhibit No.		Description
1.1		Articles of Association.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: November 12, 2026				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-1.1 EX-1.1 505.2 KB